Vertex Pharmaceuticals Incorporated – LSE:0QZU.L

Vertex Pharmaceuticals Incorporated stock price today

$220.64
-187.71
-45.97%
Financial Health
0
1
2
3
4
5
6
7
8
9

Vertex Pharmaceuticals Incorporated stock price monthly change

-16.71%
month

Vertex Pharmaceuticals Incorporated stock price quarterly change

-16.71%
quarter

Vertex Pharmaceuticals Incorporated stock price yearly change

+0.32%
year

Vertex Pharmaceuticals Incorporated key metrics

Market Cap
 101.62B
Enterprise value
 N/A
P/E
 N/A
EV/Sales
 N/A
EV/EBITDA
 N/A
Price/Sales
 N/A
Price/Book
 N/A
PEG ratio
 N/A
EPS
 15.57
Revenue
 10.18B
EBITDA
 4.73B
Income
 4.01B
Revenue Q/Q
 13.15%
Revenue Y/Y
 10.57%
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 46.48%

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Vertex Pharmaceuticals Incorporated stock price history

Vertex Pharmaceuticals Incorporated stock forecast

Vertex Pharmaceuticals Incorporated financial statements

Profit Margin

Vertex Pharmaceuticals Incorporated (LSE:0QZU.L): Profit margin
Jun 2023 2.49B 915.7M 36.73%
Sep 2023 2.48B 1.03B 41.69%
Dec 2023 2.51B 968.8M 38.48%
Mar 2024 2.68B 1.09B 40.92%
0QZU.L income statement history

Vertex Pharmaceuticals Incorporated Financials Estimate

Vertex Pharmaceuticals Incorporated (LSE:0QZU.L): Analyst Estimates
Mar 2024 2.68B 1.09B 40.92%
Sep 2025 2.88B 1.21B 42.25%
Oct 2025 2.88B 582.25M 20.16%
Dec 2025 2.99B 1.27B 42.68%

  • Analysts Price target

  • Financials & Ratios estimates

Show more

Debt to Assets

Vertex Pharmaceuticals Incorporated (LSE:0QZU.L): Debt to assets
Jun 2023 20349200000 4.87B 23.98%
Sep 2023 21726200000 5.21B 24%
Dec 2023 22730200000 5.14B 22.66%
Mar 2024 23917400000 5.37B 22.46%
0QZU.L balance sheet history

Cash Flow

Vertex Pharmaceuticals Incorporated (LSE:0QZU.L): Cash Flow
Jun 2023 1.13B -303.9M 17.3M
Sep 2023 1.26B -117.7M -165M
Dec 2023 234.6M -886.5M -119.8M
Mar 2024 1.30B -2.13B -357.5M
0QZU.L cash flow history

Vertex Pharmaceuticals Incorporated alternative data

Vertex Pharmaceuticals Incorporated
Employees

Vertex Pharmaceuticals Incorporated (LSE:0QZU.L): Employee count
Aug 2023 4,800
Sep 2023 4,800
Oct 2023 4,800
Nov 2023 4,800
Dec 2023 4,800
Jan 2024 4,800
Feb 2024 4,800
Mar 2024 5,400
Apr 2024 5,400
May 2024 5,400
Jun 2024 5,400
Jul 2024 5,400

Vertex Pharmaceuticals Incorporated other data

Vertex Pharmaceuticals Incorporated
Patents

Patent
Grant
Filling date: 31 Mar 2020 Issue date: 30 Aug 2022
Application
Filling date: 26 Jan 2022 Issue date: 18 Aug 2022
Application
Filling date: 20 Sep 2021 Issue date: 11 Aug 2022
Application
Filling date: 23 Dec 2021 Issue date: 28 Jul 2022
Application
Filling date: 17 Dec 2021 Issue date: 21 Jul 2022
Application
Filling date: 2 Feb 2022 Issue date: 7 Jul 2022
Grant
Filling date: 31 Aug 2020 Issue date: 28 Jun 2022
Application
Filling date: 25 Feb 2022 Issue date: 16 Jun 2022
Grant
Filling date: 9 Mar 2020 Issue date: 31 May 2022
Application
Filling date: 20 Aug 2021 Issue date: 7 Apr 2022
0QZU.L patents

Vertex Pharmaceuticals Incorporated
Executives

Insider Compensation
Dr. Jeffrey Marc Leiden (1956) Executive Chairman
 $4,880,000
Mr. Stuart A. Arbuckle (1966) Executive Vice President & Chief Commercial Officer $2,070,000
Dr. Reshma Kewalramani (1973) Chief Executive Officer, Pres & Director $2,030,000
Mr. Charles F. Wagner Jr. (1968) Executive Vice President & Chief Financial Officer $1,660,000
Mr. Amit K. Sachdev (1968) Executive Vice President & Chief Patient Officer
 $1,410,000
Mr. Paul M. Silva (1966) Senior Vice President & Corporation Controller $833,970
Mr. Michael J. Parini Executive Vice President & Chief Admin., Legal and Bus. Devel. Officer
Dr. David M. Altshuler Executive Vice President of Global Research & Chief Scientific Officer
Mr. Mike Tirozzi SVice President and Chief Information & Data Officer
Mr. Michael Partridge Senior Vice President of Investor Relations

Frequently Asked Questions (FAQ)

  • What's the price of Vertex Pharmaceuticals Incorporated stock today?

    One share of Vertex Pharmaceuticals Incorporated stock can currently be purchased for approximately $220.64.

  • When is Vertex Pharmaceuticals Incorporated's next earnings date?

    Unfortunately, Vertex Pharmaceuticals Incorporated's (0QZU.L) next earnings date is currently unknown.

  • Does Vertex Pharmaceuticals Incorporated pay dividends?

    No, Vertex Pharmaceuticals Incorporated does not pay dividends.

  • How much money does Vertex Pharmaceuticals Incorporated make?

    Vertex Pharmaceuticals Incorporated has a market capitalization of 101.62B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 10.51% to 9.87B US dollars.

  • What is Vertex Pharmaceuticals Incorporated's stock symbol?

    Vertex Pharmaceuticals Incorporated is traded on the LSE under the ticker symbol "0QZU.L".

  • What is Vertex Pharmaceuticals Incorporated's primary industry?

    Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.

  • How do i buy shares of Vertex Pharmaceuticals Incorporated?

    Shares of Vertex Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Vertex Pharmaceuticals Incorporated's key executives?

    Vertex Pharmaceuticals Incorporated's management team includes the following people:

    • Dr. Jeffrey Marc Leiden Executive Chairman(age: 69, pay: $4,880,000)
    • Mr. Stuart A. Arbuckle Executive Vice President & Chief Commercial Officer(age: 59, pay: $2,070,000)
    • Dr. Reshma Kewalramani Chief Executive Officer, Pres & Director(age: 52, pay: $2,030,000)
    • Mr. Charles F. Wagner Jr. Executive Vice President & Chief Financial Officer(age: 57, pay: $1,660,000)
    • Mr. Amit K. Sachdev Executive Vice President & Chief Patient Officer(age: 57, pay: $1,410,000)
    • Mr. Paul M. Silva Senior Vice President & Corporation Controller(age: 59, pay: $833,970)
    • Mr. Michael J. Parini Executive Vice President & Chief Admin., Legal and Bus. Devel. Officer
    • Dr. David M. Altshuler Executive Vice President of Global Research & Chief Scientific Officer
    • Mr. Mike Tirozzi SVice President and Chief Information & Data Officer
    • Mr. Michael Partridge Senior Vice President of Investor Relations

  • How many employees does Vertex Pharmaceuticals Incorporated have?

    As Jul 2024, Vertex Pharmaceuticals Incorporated employs 5,400 workers.

  • When Vertex Pharmaceuticals Incorporated went public?

    Vertex Pharmaceuticals Incorporated is publicly traded company for more then 10 years since IPO on 10 Nov 2014.

  • What is Vertex Pharmaceuticals Incorporated's official website?

    The official website for Vertex Pharmaceuticals Incorporated is vrtx.com.

  • Where are Vertex Pharmaceuticals Incorporated's headquarters?

    Vertex Pharmaceuticals Incorporated is headquartered at 50 Northern Avenue, Boston, MA.

  • How can i contact Vertex Pharmaceuticals Incorporated?

    Vertex Pharmaceuticals Incorporated's mailing address is 50 Northern Avenue, Boston, MA and company can be reached via phone at +61 73416100.

Vertex Pharmaceuticals Incorporated company profile:

Vertex Pharmaceuticals Incorporated

vrtx.com
Exchange:

LSE

Full time employees:

5,400

Industry:

Medical - Pharmaceuticals

Sector:

Healthcare

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

+61 73416100
50 Northern Avenue
Boston, MA 02210

:
ISIN: US92532F1003
: